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We examined the human immunodeficiency virus type 1 infectability of CD41 lymphocytes isolated from CCR5 wild-type
individuals, individuals heterozygous for the D32 allele of CCR5, and HIV-1-exposed but uninfected (EU) individuals who had
CD41 lymphocytes refractory to M-tropic viral replication. None of the EU individuals were found to be heterozygous for the
D32 allele. The CD41 lymphocytes isolated from CCR5/D32 and EU individuals were less infectable with an M-tropic viral
isolate of HIV-1 than CCR5/CCR5 control individuals but were equally as infectable with a T-tropic viral isolate. The restriction
to M-tropic viral isolate replication did not associate with any profound genotypic change in the CCR5 gene. CD41
lymphocytes from CCR5/D32 and CCR5/CCR5 EU individuals were more sensitive to the HIV-inhibitory effects of the
recombinant b-chemokines RANTES, MIP-1a, and MIP-1b than were CD41 lymphocytes from CCR5/CCR5 control individ-
uals. CD41 lymphocytes from EU individuals also showed increased sensitivity to recombinant b-chemokines and low
surface expression of CCR5. A phenotype of low CCR5 expression and high secretion of b-chemokines is associated with
reduced infectability of cells by M-tropic HIV-1. This phenotype may also be associated with protection against sexual
transmission of HIV-1. © 1998 Academic Press
INTRODUCTION
Various factors including viral phenotype, induced im-
mune responses, and host genetic factors have been
implicated in protection against transmission of the hu-
man immunodeficiency virus type 1 (HIV-1) (reviewed in
Paxton and Koup, 1996). We previously reported on the
relative resistance to in vitro infection of CD41 lympho-
cytes from a group of 25 multiply exposed individuals
(Paxton et al., 1996). Two of these individuals, EU2 and
EU3, demonstrated a lack of infectability of their CD41
lymphocytes with macrophage-tropic nonsyncytium-in-
ducing (M-tropic) isolates of HIV-1 but not with T-cell
line-adapted syncytium-inducing (T-tropic) viral isolates
(Connor et al., 1996; Paxton et al., 1996). Subsequent
studies of these individuals revealed that they were both
homozygous for a 32-bp deletion (D32) in the b-chemo-
kine receptor CCR5, an HIV-1 coreceptor required for the
entry of M-tropic viral isolates into macrophages, CD41
T lymphocytes, and microglial cells of the central ner-
vous system (Alkhatib et al., 1996; Choe et al., 1996; Deng
et al., 1996; Doranz et al., 1996; Dragic et al., 1996; He et
al., 1997; Liu et al., 1996).
There is epidemiological evidence associating the
D32 homozygous genotype with protection against the
acquisition of HIV-1 (Dean et al., 1996; Huang et al., 1996;
Samson et al., 1996b; Zimmerman et al., 1997). However,
the recent identification of a few D32 homozygous indi-
viduals who have become infected with HIV-1 indicates
that this protective effect is not absolute (Biti et al., 1997;
O’Brien et al., 1997; Theodorou et al., 1997). The majority
of studies have indicated that D32 heterozygous individ-
uals are not protected against HIV-1 transmission (Dean
et al., 1996; Huang et al., 1996). HIV-1-infected individuals
heterozygous for the D32 deletion have some advantage
over CCR5 homozygote wild-type individuals in relation
to disease progression (Dean et al., 1996; Huang et al.,
1996; Zimmerman et al., 1997). Heterozygotes are statis-
tically more likely to harbor lower viral loads, have slower
rates in CD4 lymphocyte decline, and live longer than
CCR5 wild-type individuals (Dean et al., 1996; Huang et
al., 1996; Samson et al., 1996b; Zimmerman et al., 1997).
This protection is even stronger when only subjects
infected with M-tropic viral isolates are analyzed (Mi-
chael et al., 1997).
The mechanism by which heterozygous individuals
are protected against disease progression is not fully
understood. We have previously shown that CD41 lym-
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phocytes from heterozygous individuals are less infect-
able with M-tropic viral isolates of HIV-1 in vitro (Liu et al.,
1996). We also demonstrated that in vitro infectability
correlated with CCR5 expression levels at the cell sur-
face, as measured with a CCR5-specific monoclonal
antibody (Wu et al., 1997a). Lymphocytes isolated from
D32 heterozygous individuals showed reduced CCR5
expression levels in comparison to CCR5 wild-type indi-
viduals, but there was substantial overlap in expression
levels between the two groups of individuals.
Here we sought to address the mechanism by which
some EU individuals have CD41 lymphocytes with a
reduced capacity to replicate HIV-1 in vitro (Paxton et al.,
1996). We wished to address whether the observed re-
duction in in vitro viral replication was a result of other as
yet unidentified polymorphisms within the CCR5 protein,
the phenotype of CCR5 expression at the cell surface, or
an increase in b-chemokine production levels.
RESULTS
CCR5 genotype analysis
We previously reported on the relative resistance of
CD41 lymphocytes from a group of 25 highly exposed
but uninfected individuals. Two of these individuals (EU2
and EU3) were homozygous for the 32-bp deletion in the
CCR5 gene (D32/D32) (Liu et al., 1996; Paxton and Koup,
1996). It had also been shown that two of the heterozy-
gote (CCR5/D32) parents of EU2 and EU3 had reduced
levels of M-tropic viral replication in vitro, resembling
what had been observed for some of the EU individuals
(Liu et al., 1996). We therefore wished to genotype the
remaining 23 individuals from the study group to deter-
mine whether the in vitro replication kinetics could be
explained by an overrepresentation of heterozygotes.
From the samples available we screened 21 individuals
for the CCR5 genotype. One CCR5 D32/D32 individual
was identified and no CCR5/D32 individuals, giving an
overall frequency in the cohort of 13.0% D32/D32 (3/23),
87.0% (20/23) CCR5/CCR5 wild-types, and no CCR5/D32
individuals.
Infectability of CD41 lymphocytes from EU individuals
We used both M-tropic (JR-CSF) and T-tropic (NL4-3)
isolates to infect CD41 enriched lymphocytes from 6
control CCR5 wild-type individuals (CCR5/CCR5), 4 D32
CCR5 heterozygote (CCR5/D32) controls, 2 D32 homozy-
gotes (D32/D32) and 11 selected CCR5/CCR5 EU individ-
uals. Due to the limited number of enriched CD41 lym-
phocytes not all individuals could be tested for NL4-3
infections. The EU samples tested were those which had
previously shown lower levels of M-tropic viral replica-
tion (Paxton et al., 1996). There were no statistical differ-
ences in the replication capacity of the T-tropic isolate
between any of the four groups (Table 1), although a few
of the EU individuals, specifically EU3 and EU12, had
CD41 lymphocytes with low levels of T-tropic viral repli-
cation. However, when comparing the replicative capac-
ity of the M-tropic viral isolate, differences were noted
between the CCR5/CCR5 controls and CCR5/D32 con-
trols (P 5 0.02) and between CCR5/CCR5 controls and
CCR5/CCR5 EUs (P 5 0.01). These results demonstrate
that the decreased replicative capacity in the CCR5/
CCR5 EU CD41 lymphocytes is restricted to the M-tropic
viral isolate JR-CSF and does not extend to the T-tropic
isolate NL4-3. This suggests that the observed decrease
in viral replication in the EU subjects is CCR5 related.
CCR5 gene sequence
We reasoned that the low levels of M-tropic viral rep-
lication observed in the CCR5/D32 and CCR5/CCR5 EU
TABLE 1





LP9 CCR5/CCR5 333,340 162,924
LP10 CCR5/CCR5 522,395 54,258
LP12 CCR5/CCR5 22,929 28,654
LP18 CCR5/CCR5 380,535 158,658
LP14 CCR5/CCR5 373,140 nd
LW5 CCR5/CCR5 363,180 110,312
Mean 332,586 102,961
LP19 CCR5/D32 169,974 167,316
LW8 CCR5/D32 121,788 335,120
LW9 CCR5/D32 886 129,708
LW2 CCR5/D32 103 3,222
Mean 73,182 158,841
EUs
EU2 D32/D32 0 57,006
EU3 D32/D32 0 12,194
EU5 D32/D32 0 nd
Mean — 34,600
EU1 CCR5/CCR5 13,157 75,956
EU4 CCR5/CCR5 98,555 68,214
EU6 CCR5/CCR5 75,872 nd
EU8 CCR5/CCR5 311 55,906
EU11 CCR5/CCR5 140,116 54,832
EU12 CCR5/CCR5 186,138 4,356
EU13 CCR5/CCR5 1,627 nd
EU15 CCR5/CCR5 140,850 195,454
EU17 CCR5/CCR5 11,259 nd
EU18 CCR5/CCR5 4,551 nd
EU20 CCR5/CCR5 1,253 58,928
Mean 61,244 73,378
Note. Study individuals, CCR5 genotype, and HIV-1 infectivity. CCR5
genotype was determined by PCR from genomic DNA. Infectivity was
performed on activated enriched CD41 lymphocytes. All cultures re-
ceived the same inoculum of M-tropic or T-tropic virus and p24 pro-
duction was measured on day 7; nd, not done.
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CD41 lymphocytes resulted from either differential cell
surface expression levels of the CCR5 protein or differ-
ences within the protein sequence which results in a
CCR5 molecule with a reduced efficiency for M-tropic
viral entry. To test the latter we amplified the full-length
allele of CCR5 from genomic DNA of a CCR5/D32 indi-
vidual (LW2) and both alleles from six of the CCR5/CCR5
EU individuals (EU6, 8, 12, 13, 17, and 18), all of whom had
low levels of in vitro viral replication. These genomic
amplicons were sequenced and were shown to be iden-
tical to the published CCR5 sequence (Samson et al.,
1996a). Several CCR5 clones were generated from each
genomic amplicon. Sequencing of the individual EU
CCR5 clones showed amino acid changes that did not
represent individual alleles (data not shown). These
changes are most likely to be PCR amplification or se-
quencing errors. To prove this, CCR5 from three EUs and
LW2 were cloned into the expression vector pcDNAI/
amp and were tested in a transient viral entry assay in
which 293T cells were cotransfected with pcCD4 and
CCR5 expression vectors and were infected with lucif-
erase reporter viruses pseudotyped with M-tropic (JR-FL
and ADA) or A-MLV env (Fig. 1). All of the EU CCR5
clones produced luciferase activity similar to that of the
wild-type control, suggesting that they function normally
in allowing M-tropic virus entry.
Sensitivity of CD41 lymphocytes to recombinant
b-chemokines
We further characterized the in vitro infectability of
CD41 lymphocytes from the various groups by analyzing
their sensitivity to a cocktail of recombinant b-chemo-
kines: RANTES, MIP-1a, and MIP-1b. The CCR5/D32
individuals had CD41 lymphocytes that were more sen-
sitive to the HIV-1 inhibitory effects of the recombinant
chemokines than CD41 lymphocytes from the CCR5/
CCR5 control individuals (Fig. 2a). The CD41 lympho-
cytes from the CCR5/CCR5 EUs were also more sensitive
to the recombinant chemokines than were the CCR5/
CCR5 controls but not as sensitive as the CCR5/D32
cells (Fig. 2a). These differences are evident when com-
paring the ID50 and ID90 values for the recombinant
proteins (Fig. 2b). The mean ID90 value for the CCR5/
CCR5 control CD41 lymphocytes is 140.9 6 33.1 ng/ml,
with a range of 58.0–247.0 ng/ml; the CCR5/D32 cells
have a mean ID90 value of 26.3 6 12.4, with a range of
4.7–61.1 ng/ml, and the CCR5/CCR5 EUs have a mean
ID90 value of 77.2 6 26.0 ng/ml, with a range of 15.5–204.
There was a statistical difference between the ID90 val-
ues for the CCR5/CCR5 control and CCR5/D32 individu-
als (P 5 0.03) but not between the CCR5/CCR5 controls
and CCR5/CCR5 EUs (P 5 0.15), probably a result of the
small sample size. There was, however, a trend toward
increased sensitivity to b-chemokines among the CCR5/
CCR5 EUs.
CCR5 surface expression levels
Given that the CCR5 DNA sequences from the CCR5/
CCR5 EU individuals were wild-type and that isolated
CD41 lymphocytes from these individuals were more
sensitive, in vitro, to recombinant b-chemokines, we rea-
soned that these cells may be expressing lower cell
surface levels of the CCR5 protein. We utilized monoclo-
nal antibody 2D7 to measure CCR5 expression levels on
FIG. 1. Functional analysis of CCR5 clones from three EU individuals. 293T cells were cotransfected with pcDNAI/amp expressing CCR5 from EU
individuals and pcCD4. Two days after transfection, these cells were infected with luciferase reporter viruses pseudotyped with the indicated
macrophage-tropic (JR-FL, ADA) or A-MLV Env. Luciferase activity was measured 3 days after infection as described previously (Connor et al., 1995;
Deng et al., 1996). The experiment was performed twice and for the EU individuals more than one clone was tested, with all giving similar results.
Error bars indicated standard deviation of duplicate independent measurements.
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unstimulated PBMCs from the study individuals (Wu et
al., 1997b). In addition, monoclonal antibody 12G5 was
used to measure CXCR4 expression (Endres et al., 1996).
We used unstimulated PBMCs so as not to introduce
error in expression levels due to in vitro stimulation.
Monoclonal antibody 2D7 is able to stain cells in the
absence of previous in vitro stimulation. The results of
staining PBMCs from CCR5/CCR5 control, CCR5/D32
control, and CCR5/CCR5 EU individuals are shown in Fig.
3a. When comparing the three groups by mean fluores-
cence intensity (MFI) a statistical difference was ob-
served between CCR5/CCR5 control and CCR5/CCR5 EU
individuals (P 5 0.01) for 2D7, but not 12G5 staining. The
difference in 2D7 staining between the CCR5/CCR5 con-
trol and CCR5/D32 control individuals did not reach sta-
tistical significance (P 5 0.07), most likely a reflection of
the small number of CCR5/D32 individuals analyzed. We
have previously shown in a larger group of subjects that
there is a clear difference in surface expression of CCR5
between these groups (Wu et al., 1997a). The two EU
individuals, EU3 and EU12, with the CD41 lymphocytes
that demonstrated low infectability with a T-tropic viral
isolate had 12G5 staining profiles similar to those of the
other individuals.
FIG. 2. Sensitivity of CD41 enriched lymphocytes to recombinant b-chemokines. CD41 enriched lymphocytes from CCR5/CCR5 control, CCR5/D32
control, or CCR5/CCR5 EUs were utilized in inhibition studies with variant (23 dilutions) of a cocktail of the recombinant chemokines RANTES, MIP-1a,
and MIP-1b (starting concentration of 500 ng of each recombinant chemokine). The plots for percentage of viral inhibition in the presence of variant
chemokine concentrations can be seen for each group in (a) and a plot of the calculated ID50 and ID90 values for each group can be seen in (b), with
the mean values indicated as a bar.
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A significant correlation was also noted between re-
combinant b-chemokine inhibition and CCR5 surface ex-
pression levels (P , 0.05, r2 5 0.26) but there was no
difference between ID50 values and CXCR4 surface ex-
pression levels. This suggests that levels of CCR5 sur-
face expression directly affect the ability of b-chemo-
kines to block M-tropic virus infection.
RANTES secretion levels
We also anticipated that high levels of endog-
enously produced b-chemokines might directly restrict
HIV-1 entry and replication in vitro. Previously we had
shown that enriched CD41 lymphocytes from two D32/
D32 individuals secreted 5- to 10-fold higher levels of
the b-chemokines RANTES, MIP-1a, and MIP-1b than
CD41 lymphocytes from two CCR5/CCR5 control indi-
viduals (Paxton et al., 1996). We measured the levels of
RANTES being secreted from both PBMCs and en-
riched CD41 lymphocytes for representative individu-
als from all four groups. These results are shown in
Fig. 3b. Although no statistical differences were found
between any of the groups, the CD4 lymphocytes from
a proportion of the CCR5/D32 control and CCR5/CCR5
EU individuals secreted higher levels of RANTES than
the CCR5/CCR5 control individuals.
A statistical correlation was noted between RANTES
secretion levels from enriched CD41 lymphocytes and
recombinant b-chemokine inhibition (ID90) levels (P ,
0.05, r2 5 0.29) but not between ID90 values and RANTES
secretion levels from PBMCs.
DISCUSSION
The mechanism of decreased in vitro infectability of
CD41 lymphocytes in EU individuals is not completely
explained by the D32 CCR5 allele. From an original
cohort of 25 EU individuals we selected 11 whose CD41
enriched lymphocytes demonstrated intermediate levels
of M-tropic viral replication. We wished to address
whether CCR5 genotype or phenotype was contributing
to resistance to infection.
When the remainder of the individuals in the study
cohort were genotyped for the D32 allele, one additional
D32/D32 was identified (EU5) and no CCR5/D32 individ-
uals were found. This provides an overall frequency in
the cohort of 13.0% of D32/D32 individuals, supporting
the correlation of this genotype with protection against
the sexual transmission of HIV-1 (Dean et al., 1996;
Huang et al., 1996; Samson et al., 1996b; Zimmerman et
al., 1997). An interesting observation is that all three of
the D32/D32 individuals belonged to the group of homo-
sexual men who had reported sexual encounters with
multiple partners (Paxton et al., 1996). This high fre-
quency (three of seven, 42.9%) in such a high-risk group
further strengthens the premise that this genotype is
overrepresented in the most highly exposed uninfected
groups (Huang et al., 1996). There have been recent
reports describing D32/D32 individuals that are HIV-1
infected but none have yet described any D32/D32 indi-
vidual as being specifically infected with an M-tropic,
NSI, viral isolate (Biti et al., 1997; O’Brien et al., 1997;
Theodorou et al., 1997). No heterozygous individuals
were identified in our EU population. The relative resis-
tance of CD41 lymphocytes to M-tropic viral isolates
within this cohort is therefore not a result of an overrep-
resentation of CCR5 D32 heterozygotes. We also con-
clude that the reduced replicative capacity of M-tropic
viral isolates in the CCR5/CCR5 EU individuals is at the
level of the CCR5 protein since CD41 lymphocytes from
FIG. 3. Chemokine surface expression levels and b-chemokine secretion levels. CCR5 and CXCR4 cell surface expression levels were measured
on unstimulated PBMCs and plotted as mean fluorescence intensity (MFI) for each group and can be seen in (a) with the mean value indicated by
a bar. The RANTES levels (pg/ml) secreted from either PBMC fractions or CD41 enriched lymphocytes can be seen in (b), with the mean levels
indicated by a bar.
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these individuals were as readily infectable with the
T-tropic strain NL4-3 as were the CD41 lymphocytes
from CCR5/CCR5 control individuals.
The gene coding for CCR5 could be highly polymor-
phic; other alleles potentially exist which could alter
the protein’s capacity to function as an efficient core-
ceptor for HIV-1 entry. When tested directly, no DNA
sequence variations were found in any of the CCR5
alleles from the selected individuals whose CD41 lym-
phocytes demonstrated the lowest levels of M-tropic
viral replication, nor did the amplified clones show any
reduced efficiency of HIV-1 entry into transfected 293/
CD4 cells in vitro (Fig. 1). Therefore, the reduced
infectability of CD41 lymphocytes from CCR5/CCR5 EU
individuals was not due to previously unrecognized
alleles within the CCR5 coding region.
Our study demonstrates that the CD41 lymphocytes
from the CCR5/D32 and CCR5/CCR5 EU individuals are
generally more sensitive to the effects of recombinant
b-chemokines, have lower levels of CCR5 expression,
and secrete higher levels of RANTES than do those of
the CCR5/CCR5 control individuals. We found a twofold
reduction in CCR5 cell surface expression levels in the
CCR5/CCR5 EU individuals compared to controls. This
level of expression is similar to what is commonly ob-
served in CCR5/D32 individuals and could explain the
reduced infectability of their CD41 lymphocytes to M-
tropic virus (Table 1, Fig. 3a). In addition, the reduction in
coreceptor expression occurs in the presence of higher
endogenous secretion of RANTES, possibly leading to an
enhanced antiviral effect. This combined effect is further
demonstrated by the increased sensitivity of the CD41
lymphocytes from the CCR5/D32 and CCR5/CCR5 EU
individuals to recombinant b-chemokines in comparison
to CCR5/CCR5 controls. Our data are consistent with
less b-chemokine being required to saturate the low
level of CCR5 on the CCR5/D32 and CCR5/CCR5 EU
cells, leading to more efficient blocking of the receptor
from use by HIV-1. It is therefore likely that the combined
effects of low surface expression of CCR5 and high
secretion of b-chemokines are responsible for the lack of
infection in many of our EU individuals. It should be
noted that the donors with the least infectable CD41
lymphocytes had no one distinguishable characteristic.
The low infectability with a T-tropic virus of CD41 lym-
phocytes from two EUs, EU3 and EU12, could not be
explained by lower levels of CXCR4 expression at the
cell surface.
On a more cautious note, we must be careful not to
overinterpret these results. If we assume that a lowering
of CCR5 cell surface expression levels has an effect on
transmission of HIV-1, we would expect to find an in-
creased frequency of CCR5/D32 individuals in the EU
populations. Only one study to date has suggested that
this genotype can protect against viral transmission
(Samson et al., 1996b); several other studies disagree
with this conclusion (Dean et al., 1996; Huang et al., 1996;
Zimmerman et al., 1997). It is therefore likely that the
increased production of b-chemokines, decreased sur-
face expression levels of CCR5, and increased sensitivity
to the antiviral effects of the b-chemokines among the
CCR5/CCR5 EU subjects are only partially responsible
for this in vivo protection against HIV-1 infection. Other
factors are likely to be involved.
Our findings also have significance for the pathogen-
esis of HIV-1 infection. We and others have reported that
the CCR5/D32 genotype protects against disease pro-
gression (Dean et al., 1996; Huang et al., 1996; Zimmer-
man et al., 1997). Based upon the work presented here it
is possible that lower levels of CCR5 and increased
b-chemokine secretion levels from CD41 lymphocytes of
some CCR5/CCR5 individuals may also protect against
disease progression. In fact, CCR5 expression on PB-
MCs varies significantly between individuals (Wu et al.,
1997). We would predict that it is often the phenotype of
CCR5 expression rather than the CCR5 genotype that is
important in protection against disease progression.
This phenotype may be linked to genotypes within
CCR2b and SDF-1 that have recently been shown to
protect against disease progression (Smith et al., 1997;
Winkler et al., 1998).
The mechanism behind the low cell surface expres-
sion of CCR5 in CCR5/CCR5 individuals remains to be
determined. There may be mutations within the promoter
region of the gene or differences in transcriptional trans-
activation in these CD41 lymphocytes that alter the
CCR5 mRNA levels. Additionally, there may be posttran-
scriptional events that account for the differences in
CCR5 expression in CD41 lymphocytes between individ-
uals. Further work in this area is needed. In the interim,
measuring surface expression of CCR5 may provide im-
portant information into how coreceptor expression af-
fects HIV-1 transmission and disease progression.
MATERIALS AND METHODS
Study individuals
The EU individuals were all taken from a previously
described cohort of persons who had been exposed to
HIV through multiple high-risk sexual encounters (Paxton
et al., 1996). The control individuals were either random
Leukopac donors (LP) or laboratory workers (LW).
CCR5 genotyping
A portion of the CCR5 gene was amplified by PCR from
genomic DNA (extracted via DNA/RNA isolation kits,
USB, Cleveland, OH) and analyzed on a 4% Metaphor
agarose gel. The primers CCR5c, 59-CAAAAAGAAG-
GTCTTCATTACACC-39, and CCR5d, 59-CCTGTGCCTCT-
TCTTCTCATTTCG-39, that flank the 32-bp deletion were
used to generate wild-type and deleted fragments of 189
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and 157 bp, respectively. The PCR reaction mixture con-
tained 0.25 mM dNTPs, 20 pmol of each primer, and 0.5
unit of Taq polymerase in 13 reaction buffer (Promega,
Madison, WI). Each PCR amplification consisted of 42
cycles, with the first 5 cycles of 94°C for 45 s, 50°C for
45 s, 72°C for 45 s, followed by 37 cycles of 94°C for 45 s,
60°C for 45 s, and 72°C for 45 s.
Cloning and sequencing of the CCR5 gene
The CCR5 gene was amplified from genomic DNA
using primers flanking the coding region, 59-CTCGGATC-
CGGTGGAACAAGATGGATTAT, 59-CTCGTCGACATGTGC-
ACAACTCTGACTG, with Expand polymerase (Boehringer
Mannheim) by 5 cycles of PCR (94°C, 30 s; 55°C, 45 s;
72°C, 90 s) followed by an additional 35 cycles (94°C,
30 s; 62°C, 45 s; 72°C, 90 s) in 100 ml. Only the full-length
allele was amplified from heterozygous (CCR5/D32)
genomic DNA using a pair of overlapping primers that
would hybridize to the deleted 32 bp, 59-GTCTGGAAAT-
TCTTCCAGAATTGATAC, 59-GTATCAATTCTGGAAGAATT-
TCC. The PCR products were either sequenced directly
or cloned into the expression vector pcDNA/amp (Invitro-
gene Corp.) and then sequenced using either the
dideoxy method or high-density oligonucleotide arrays
(Kozal et al., 1996).
CD4 infectability and recombinant chemokine
sensitivities
All cells utilized in this study were isolated from pre-
viously cryopreserved peripheral blood mononuclear
cells (PBMC). Cells were thawed and stimulated with
PHA (5 mg/ml) and carried in culture medium (RPMI 1640
supplemented with antibiotics and 10% fetal bovine se-
rum) containing interleukin-2 (100 units/ml) (Hoffman–
LaRoche, Nutley, NJ). The cells were carried for 7 days.
Half the medium was replaced with fresh culture medium
containing IL-2 every 2–3 days. On day 7 the cells were
enriched for CD41 lymphocytes by depleting the culture
of the CD81 cells using immunomagnetic beads (DY-
NAL, Great Neck, NJ). Viral infections were set up using
2.0 3 105 CD41 enriched lymphocytes per well of flat-
bottomed 96-well plates with a 3000 median tissue cul-
ture infectious dose (TCID50) of the M-tropic isolate JR-
CSF and separately the T-tropic virus pNL4-3 (m. o. i. 5
0.003). Cells were cultured for 7 days and fed on day 4
with fresh interleukin-2 containing media. Viral growth
was determined on day 7 by measuring p24 antigen
levels using an immunoassay (Abbott Laboratories, Ab-
bott Park, IL). The sensitivity of the CD41 enriched lym-
phocytes to b-chemokines was assessed by incubating
1.0 3 105 of the above-described cells (100 ml/well in flat
bottomed 96-well plates) with varying quantities of the
recombinant chemokines RANTES, MIP-1a, and MIP-1b
(R & D Systems, Minneapolis, MN). All three chemokines
were mixed in a cocktail with a starting concentration of
1000 ng/ml of each recombinant chemokine. Twofold
dilutions of this initial cocktail were made down to 3.9
ng/ml, and 100 ml of each was added to separate wells
of CD41 enriched lymphocytes. A control well containing
media alone was included in all assays. Each well was
inoculated with 3000 TCID50 of the M-tropic viral isolate
JR-CSF. The cultures were carried for 7 days and fed with
fresh interleukin-2 containing media on day 4. Viral ac-
tivity was measured as described above on day 7 and
viral inhibition determined as the percentage of p24
reduction, in the presence of recombinant chemokine,
compared to the control well. The chemokine concentra-
tions required to inhibit p24 production by 50 or 90% (ID50
and ID90 values) were calculated using linear regression
analysis. The results presented were from single exper-
iments that were reproducible.
RANTES secretion levels
Seven-day activated PBMCs or CD41 enriched lym-
phocytes were plated at 1.0 3 106/well in a 24-well plate
and cultured for a further 4 days. The supernatants were
harvested and RANTES levels determined using a com-
mercially available immunoassay (R & D Systems). The
results presented were from single experiments that
were reproducible.
CCR5 and CXCR4 surface expression levels
FACS analysis was performed on unstimulated PM-
BCs using the 2D7 (Wu et al., 1997b) and 12G5 (Endres et
al., 1996) monoclonal antibodies to determine CCR5 and
CXCR4 expression levels at the cell surface, respectively.
The 2D7 and 12G5 antibodies were used as purified
antibody and utilized at a working concentration of 8 and
1.7 mg/ml, respectively. The antibodies were incubated
with 2.0 3 105 cells in 50 ml PBS/5%FCS/0.01% sodium
azide solution for 30 min on ice. Isotype-matched mouse
monoclonal antibodies were used as controls (IgG1 for
2D7 and IgG2a for 12G5, Caltag, San Francisco, CA).
Cells were washed three times with PBS containing 5%
FCS and 0.01% sodium azide before being incubated
with a 1:50 dilution of a RPE-conjugated goat anti-mouse
antibody (DAKO Inc., Capinteria, CA). The cells were
incubated for 30 min on ice and again washed three
times before being fixed in 1% formaldehyde. Surface
staining was analyzed with a FACS calibur machine
(Becton–Dickinson, San Jose, CA).
Statistical analysis
The unpaired Student’s t test was used to compare
similar parameters between two separate groups of in-
dividuals. Regression analysis was used when compar-
ing two different parameters. In both tests P values of
,0.05 were considered significant.
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